Institutional Ownership: CVS Health has significant institutional ownership, with institutions holding 87% of the shares, indicating that the stock price is sensitive to their trading actions.
Major Shareholders: The top 13 shareholders collectively own 51%, with BlackRock being the largest shareholder at 9.7%, followed by Vanguard and Capital Research.
Insider Ownership: Insiders own less than 1% of CVS Health, which suggests limited influence from company management on stock performance, though they collectively hold $91 million in stock.
Public Influence: The general public, including retail investors, owns 12% of the company, which can impact how CVS Health is managed despite not having majority control.
CVS
$78.29+Infinity%1D
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 90.53 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 90.53 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 79.690
Low
75.00
Averages
90.53
High
102.00
Current: 79.690
Low
75.00
Averages
90.53
High
102.00
Bernstein
Bernstein
Market Perform
maintain
$86 -> $87
2025-12-12
New
Reason
Bernstein
Bernstein
Price Target
$86 -> $87
2025-12-12
New
maintain
Market Perform
Reason
Bernstein raised the firm's price target on CVS Health to $87 from $86 and keeps a Market Perform rating on the shares following overall a very positive Investor Day event. The firm cites increased confidence in quality and depth of management teams, and reinforcement of the quality and market leadership of leading companies.
Baird
Outperform
maintain
$82 -> $92
2025-12-10
Reason
Baird
Price Target
$82 -> $92
2025-12-10
maintain
Outperform
Reason
Baird raised the firm's price target on CVS Health to $92 from $82 and keeps an Outperform rating on the shares. The firm updated its model and believes its bull thesis remains intact.
Mizuho
Ann Hynes
Outperform
maintain
$88 -> $95
2025-12-10
Reason
Mizuho
Ann Hynes
Price Target
$88 -> $95
2025-12-10
maintain
Outperform
Reason
Mizuho analyst Ann Hynes raised the firm's price target on CVS Health to $95 from $88 and keeps an Outperform rating on the shares, telling investors that the company provided "several positive updates" at its bi-annual investor day, including updated 2025 guidance, detailed 2026 guidance, and a raised long-term earnings growth outlook. CVS is the top pick in the analyst's coverage universe, the analyst noted.
Truist
Buy
maintain
$95 -> $98
2025-12-10
Reason
Truist
Price Target
$95 -> $98
2025-12-10
maintain
Buy
Reason
Truist raised the firm's price target on CVS Health to $98 from $95 and keeps a Buy rating on the shares. The firm remains bullish on CVS post an upbeat Investor Day highlighting the company's differentiated collection of assets, strong positioning and opportunities across segments, alongside the announced launch of a centralized engagement platform in FY26, the analyst tells investors in a research note. Brisk cash flow and ongoing balance sheet improvement underpins continued core growth investment, the firm added.
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
